For research use only. Not for therapeutic Use.
Des-acetyl Apremilast (CAT: C000621) is a metabolite derived from Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor. Apremilast is utilized in the treatment of psoriatic arthritis, a chronic inflammatory condition affecting the joints and often associated with psoriasis. The conversion of Apremilast to its metabolite, Des-acetyl Apremilast, highlights the importance of metabolic pathways in drug action and elimination from the body. While Apremilast targets PDE4 to modulate inflammatory responses, further research is needed to elucidate the specific role and significance of its metabolite, Des-acetyl Apremilast, in the context of treatment efficacy, pharmacokinetics, and potential interactions.
Catalog Number | C000621 |
CAS Number | 635705-72-5 |
Synonyms | 4-Amino-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1H-isoindole-1,3(2H)-dione; |
Molecular Formula | C₂₀H₂₂N₂O₆S |
Purity | ≥95% |
Solubility | Chloroform (Slightly), DMSO (Slightly) |
Appearance | Off-White to Yellow Solid |
Storage | 4°C, Inert atmosphere |
Reference | Hoffmann, M., et al.: Xenobiotica, 41, 1063 (2011); Gan, E., et al.: BioDrugs, 27, 359 (2013); Pathan, E., et al.: Annal. Rheum. DIs., 72, 1475 (2013); |